viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals: 'Benefit from strong suite of capabilities to deliver on strategy'

Proactive Research analyst Ed Stacey presents his research on MGC Pharmaceuticals (LON:MXC) a biopharma company which develops drugs from plant-based sources, including cannabis.

He tells Presenter Katie Pilbeam there are also non cannabis products which could be the real big value drivers in the next 12 months. Ed also explains how the firms’ cannabis extracts for the medical cannabis market, the biggest for them is Australia, are growing fast.

MGC has various clinical trials and development programmes currently underway and two of them that are quite far advanced proprietary formulations from cannabis targeting drug resistant epilepsy and targeting symptoms related to dementia. Stacey says these are both in phase two trials.

Click here to read Proactive analyst Ed Stacey's Initiation Report on MGC Pharmaceuticals

Quick facts: MGC Pharmaceuticals Ltd


Price: 3.25 GBX

Market Cap: £77.5 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

4 days, 8 hours ago

2 min read